

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$13.28**

Change (%) **▼ 0.13 (0.90%)**

Volume 301,831

52 Week High \$19.90

52 Week Low \$4.45

Market Cap \$1,200,846,588

Rolling EPS -1.39

PE Ratio 0

Shares Outstanding 89,615,417

Data as of June 19, 2018 1:15 p.m. ET



Recent Headlines

June 7, 2018

[Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma](#)

May 31, 2018

[Iovance Biotherapeutics to Present at Two Investor Conferences in June](#)

May 10, 2018

[Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update](#)

SEC Filings

Filing Date	Form
June 8, 2018	8-K
June 7, 2018	8-K
May 10, 2018	8-K
May 10, 2018	10-Q

Data provided by Nasdaq. Minimum 15 minutes delayed.

Upcoming Events

Date	Title
June 20, 2018 1:00 p.m. ET	Iovance Biotherapeutics, Inc. at JMP Securities Life Sciences Conference

Corporate Governance

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.